Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Journal Title: OncoReview - Year 2015, Vol 5, Issue 4
Abstract
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors. Combined with capecitabine, it is administered in patients suffering from advanced breast cancer with HER-2 receptor overexpression.The present article analyses data obtained from medical records of 24 breast cancer patients treated with lapatinib and capecitabine in the years 2010–2015, in order to examine the treatment-related toxicity. The major adverse effects observed under treatment included diarrhoea, nausea, emesis, skin toxicity, and elevated transaminases. In 3 patients, grade 3 adverse events were reported, as assessed in accordance with CTCAE. The most frequent cause behind the cessation of treatment was disease progression. The analysis has indicated that lapatinib plus capecitabine is a well tolerated treatment regimen.
Authors and Affiliations
Zuzanna Borysiewicz, Iwona Ryniewicz-Zander
Keywords
Related Articles
- EP ID EP78729
- DOI 10.5604/20828691.1189750
- Views 210
- Downloads 0
“Life-saving” inappropriate implantable cardioverter-defibrillator shocks in a cancer patient
Impaired left ventricular ejection fraction (LV EF) in patients with cancer can disqualify them from targeted antineoplastic treatment. We present the case of 63-year-old male with gastric cancer treated palliatively, wi...
The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objecti...
Predicting heart attack in a patient post-radiation therapy using plaque CCTA analysis and serum biomarker test. Case report
Accelerated coronary artery disease (CAD) is a long term manifestation of chest irradiation that may progress to acute myocardial infarction (MI). We report the use of an algorithm-based biomarker test and coronary compu...
Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors....
Distress and depression in cancer patients - diagnosis and treatment
Cancer diagnosis destroys previous internal and external order of patient, who has not experienced such a situation yet. The most negative emotions, which are felt in the situation of cancer diagnoses are anxiety, sadnes...